Long-term effects of entecavir and tenofovir treatment on the fibrotic burden in patients with chronic hepatitis B.
Young Eun ChonSeung-Up KimYeon Seok SeoHye-Won LeeHan Ah LeeMi Na KimYun Ho RohJun Yong ParkDo Young KimSang Hoon AhnWon Young TakSoo Young ParkBeom Kyung KimPublished in: Journal of gastroenterology and hepatology (2021)
Significant regression of APRI and FIB-4 was observed during long-term ETV and TDF treatment. Despite higher baseline fibrotic burden in ETV group, fibrotic burden between the groups eventually converged through significant fibrosis regression after 1 to 4 years of AVT.